Thymosin Alpha 1 Plus Anti-PD-1 for Advanced Melanoma in Older Adults
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs—thymosin alpha 1 (an immune-boosting protein) and an anti-PD-1 antibody (a cancer immunotherapy)—in patients 60 and older with advanced melanoma that cannot be surgically removed. The goal is to help the immune system fight the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 60 years old or older
- Have advanced melanoma (stage III or IV) that cannot be removed by surgery, confirmed by biopsy
- Have at least one tumor that can be measured on imaging scans
- Have reasonable overall health (ECOG score 0–2, meaning you can do light to moderate activities)
- Have normal or near-normal liver and kidney function blood tests
- Not have had certain immunotherapy drugs (PD-1, PD-L1, or CTLA-4 inhibitors) in the past 6 months, or if you did, you must have progressed at least 6 months after treatment ended
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy treatments for advanced melanoma that has not responded to standard therapy. The goal is to use your own immune cells to fight the cancer more effectively.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial tests a new treatment called ADP-TILIL7 for people with advanced melanoma. It uses your own immune cells (T-cells) that are taken from a tumor, multiplied in a lab, and then given back to you to fight the cancer. The goal is to see if this treatment is safe and works better than standard options.
This trial tests a special type of immune cells (gamma-delta T cells) given with either interferon or a PD-1 inhibitor for people with stage III-IV melanoma that can be removed with surgery. The goal is to see if this combination helps the immune system fight the cancer and prevent it from coming back.
This trial tests a combination of three drugs (interferon, an immunotherapy drug called toripalimab, and an anti-cancer drug called anlotinib) in people with advanced melanoma that cannot be removed with surgery. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a treatment made from your own immune cells (called tumor-infiltrating lymphocytes). The cells are taken from a tumor sample, multiplied in a lab, and given back to you to help fight the cancer. It's for people with melanoma that has not responded to standard immunotherapy.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.